All In MedTech

FDA Clearance Tracker · P100049-S037

LINX Reflux Management System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 22, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 22, 2024

Approved

Time to decision

87 days

Received Nov 27, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P100049-S037
Device name
LINX Reflux Management System
Applicant
Torax Medical
Applicant location
Cincinnati, OH
Received
Nov 27, 2023
Decided
Feb 22, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P100049

Device type

Device class
Class III

Every decision under product code LEI

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE FOLLOWING LABELING UPDATES:1) Removal of Barrett's Esophagus (BE) from a precaution statement in the instructions for use. LINX has not been demonstrated to be an effective treatment that leads to BE regression or prevention of progression to cancer. As such, patients with BE who are treated with LINX for management of GERD symptoms should consult with their physician for continued treatment of BE (including PPI use).2) Addition of a "Clinical Data Summary" section that describes a single observational study that supports safe use of the LINX device to treat GERD symptoms in patients with known BE3) Updates to the Patient Information Booklet to align with changes to the instructions for use.

Source documents

Other decisions for Torax Medical

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.